Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

M. Baeten, Jared; Palanee‐Phillips, Thesla; R. Brown, Elizabeth; Schwartz, Katie; Soto‐Torres, Lydia; Govender, Vaneshree; Mgodi, Nyaradzo; Matovu Kiweewa, Flavia; Nair, Gonasagrie; Mhlanga, Felix; Siva, Samantha; Bekker, Linda‐Gail; Jeenarain, Nitesha; Gaffoor, Zakir; Martinson, Francis; Makanani, Bonus; Pather, Arendevi; Naidoo, Logashvari; Husnik, Marla; A. Richardson, Barbra; M. Parikh, Urvi; W. Mellors, John; A. Marzinke, Mark; W. Hendrix, Craig; van der Straten, Ariane; Ramjee, Gita; M. Chirenje, Zvavahera; Nakabiito, Clemensia; E. Taha, Taha; Jones, Judith; Mayo, Ashley; Scheckter, Rachel; Berthiaume, Jennifer; Livant, Edward; Jacobson, Cindy; Ndase, Patrick; White, Rhonda; Patterson, Karen; Germuga, Donna; Galaska, Beth; Bunge, Katherine; Singh, Devika; Szydlo, Daniel; Montgomery, Elizabeth; Mensch, Barbara; Torjesen, Kristine; I. Grossman, Cynthia; Chakhtoura, Nahida; Nel, Annaléne; Rosenberg, Zeda; McGowan, Ian; L. Hillier, Sharon

doi:10.1056/nejmoa1506110

Public

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

Published in New England Journal of Medicine • Feb 22, 2016

Authors:

Jared M. Baeten

Thesla Palanee‐Phillips

Elizabeth R. Brown

Abstract

BACKGROUND: Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence. Longer-acting me...

Subject

Medicine

Incidence (geometry)

Vaginal ring

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!